Dr. Marty Makary resigned as Food and Drug Administration commissioner on Tuesday, ending a turbulent 14-month tenure that drew fierce criticism from pharmaceutical companies, physicians, and patient advocacy groups over high-profile drug rejections and internal agency dysfunction.
Market Context
The resignation arrives at a critical juncture for the biopharmaceutical sector. The industry is currently negotiating the reauthorization of the Prescription Drug User Fee Act (PDUFA), which outlines the fees collected from drugmakers to fund FDA reviews. Any leadership transition during this period introduces additional uncertainty into an already complex regulatory landscape. Healthcare sector ETF XLV fell 0.8% in afternoon trading following news of the resignation.
Analysis
Makary's departure follows weeks of reporting that the White House planned to oust him, with Health and Human Services Secretary Robert F. Kennedy Jr. making the final decision, according to a senior administration official. The commissioner faced mounting backlash over his handling of rare disease treatment approvals, including rejections of therapies from companies such as Replimune and uniQure. The FDA's initial refusal to review Moderna's flu shot and Makary's critical remarks about gene therapies created friction with biotech investors and industry stakeholders.
Staff morale at the agency had deteriorated significantly under Makary's leadership. Career scientists, including longtime cancer regulator Dr. Richard Pazdur, departed citing concerns over management decisions. Among Makary's most polarizing appointees was Vinay Prasad, a key official overseeing vaccines and biotech treatments who stepped down in late April after mounting criticism from the pharmaceutical industry.
The political dimensions of the vacancy extend beyond regulatory policy. The Susan B. Anthony Pro-Life America organization had pushed for Makary's removal over the FDA's handling of the abortion pill mifepristone, which he reportedly slow-walked for safety review. President Donald Trump named Kyle Diamantas, previously the agency's top food official, as acting commissioner.
Key Numbers
- 14 months: Duration of Makary's tenure as FDA commissioner
- $1.1 billion: Annual PDUFA fees collected from pharmaceutical companies under current authorization
- 0.8%: Decline in Healthcare Select Sector SPDR Fund (XLV) following resignation announcement
- April 2026: Month when Replimune received its second rejection for melanoma treatment candidate
What to Watch
Trump will need to secure Senate confirmation support, likely requiring backing from Sen. Bill Cassidy, R-La., a former physician who nearly blocked Kennedy's HHS confirmation. However, Trump's endorsement of Cassidy's primary challenger could complicate negotiations. Markets should monitor whether Diamantas maintains continuity in drug review timelines during the transition period, particularly for companies awaiting decisions on rare disease treatments that were rejected under Makary's leadership.
The PDUFA reauthorization process will now proceed with interim FDA leadership, potentially affecting negotiating leverage for pharmaceutical companies seeking fee structures favorable to expedited approvals. Investors should track whether any new commissioner nominee signals a shift in the FDA's approach to accelerated approval pathways and gene therapy evaluations.